Assay Report
Methods · Standard Curves · QC · Results
End-to-end custom single-molecule digital immunoassay development, antibody pairing optimization, EDC/NHS magnetic bead conjugation, and fit-for-purpose bioanalytical method validation on Quanterix Simoa HD-X and SR-X platforms.
When commercial immunoassay kits lack the required sensitivity or target novel proprietary drug candidates, Creative Proteomics converts your matched antibody pairs or standard plate ELISAs into digital single-molecule assays. Achieve up to 1,000-fold sensitivity gains, sub-picogram LLOQs, and 100% basal detectability from micro-volumes. We deliver complete assay dossiers and validated SOPs.
A structured, stage-gated development framework ensuring maximum sensitivity gains and rigorous bioanalytical validation.
Creative Proteomics executes custom Simoa assay development through a structured 4-phase milestone pathway:
| Development Phase | Core Technical Activities Performed | Key Analytical Checkpoint | Expected Milestone Output |
|---|---|---|---|
| Phase 1: Feasibility & Screening | Antibody screening, epitope binning, SPR/Biacore affinity assessment, initial EDC/NHS bead coupling test. | Specific signal induction (AEB) over background buffer blank. | Go/No-Go Feasibility Summary & optimal antibody orientation. |
| Phase 2: Assay Optimization | Bead coating concentration optimization, biotinylation D/P ratio titration, SBG enzyme concentration, incubation kinetics. | Signal-to-background ratio optimization and non-specific binding suppression. | Optimized assay formulation & preliminary standard curve. |
| Phase 3: Matrix Qualification | Matrix dilution linearity (MRD), spike-and-recovery in biological biofluids (plasma/CSF), heterophilic blocking. | Parallelism & spike recovery between 80% and 120%. | Validated biological matrix dilution & LLOQ confirmation. |
| Phase 4: Full Method Validation | Comprehensive fit-for-purpose validation (precision, dynamic range, freeze-thaw stability, batch robustness). | Intra-assay CV <10%, inter-assay CV <15%, 8-point 4PL curve fit. | Comprehensive Method Validation Dossier, Custom SOP, Production-Ready Reagents. |
Tailored custom digital assay capabilities spanning diverse analyte classes and complex sample matrices.
| Service Capability | Technical Scope & Methodology | Target Molecule Types | Key Research Benefit |
|---|---|---|---|
| ELISA-to-Simoa Conversion | Direct transfer of existing 96-well ELISA antibody pairs onto Simoa paramagnetic beads. | Commercial or in-house sandwich ELISA targets | Achieve 100- to 1,000-fold sensitivity enhancement without redesigning biological antibodies. |
| De Novo Novel Biomarkers | De novo assay development from proprietary hybridoma clones, recombinant mAbs, or Fab fragments. | Proprietary drug targets, neoantigens, rare proteoforms | Establish bespoke ultra-sensitive bioassays for first-in-class therapeutic programs. |
| Custom Multiplex Panels | Engineering multi-analyte assays (2-plex, 3-plex, 4-plex) using fluorescently dye-encoded bead codes. | Targeted multi-biomarker disease panels | Simultaneous multi-target quantification from a single 15 μL sample aliquot. |
| Circulating miRNA & Nucleic Acids | Probe-based single-molecule bead hybridization on Simoa SR-X without PCR amplification. | Circulating microRNAs, non-coding RNAs, ASOs | Direct femtomolar nucleic acid quantification without reverse transcription or PCR bias. |
Evaluating custom assay development capabilities, multiplexing limits, and sample conservation during method migration.
| Technical Dimension | Plate-Based Sandwich ELISA | Luminex xMAP Custom Beads | MSD ECL (R-PLEX) Platform | Quanterix Simoa Custom Assay (Our Service) |
|---|---|---|---|---|
| Typical Custom LLOQ | 10.0 – 50.0 pg/mL | 1.0 – 10.0 pg/mL | 1.0 – 5.0 pg/mL | 0.01 – 0.10 pg/mL (Sub-pg/mL / fg/mL) |
| Sample Consumption per Test | 50 – 100 μL (Neat) | 25 – 50 μL | 25 – 50 μL | 15 μL net volume (1:4 dilution) |
| Custom Multiplex Flexibility | Singleplex (1 target/well) | High Multiplex (Up to 50–100 plex) | Medium Multiplex (1–10 plex) | Focused Low-Plex (1–4 plex) |
| Dynamic Quantification Range | 2.0 logs | 3.0 – 3.5 logs | 3.5 – 4.0 logs | >4.5 logs (Poisson digital + Analog) |
| Basal Blood Detectability | <20% (High dropout rate) | 50% – 70% (Baseline dropout risk) | 60% – 80% (CSF optimal; plasma variable) | 100% Quantifiable across healthy cohorts |
| Serial Micro-Sampling in Rodents | Poor (Requires terminal pooling) | Moderate | Moderate | Excellent (Tail-vein / serial live draws) |
| Development Reagent Requirements | Standard antibodies (0.1 mg) | Magnetic Luminex microspheres | R-PLEX linkers / MSD plates | EDC/NHS paramagnetic carboxyl beads |
When transitioning ongoing drug discovery programs from standard ELISA, Luminex, or MSD to custom Simoa, establishing formal method bridging is critical. Because digital single-molecule counting eliminates bulk optical baseline noise, absolute numerical values will show a predictable proportional shift while maintaining strong linear correlation (r > 0.95).
Our Bridging Protocol: We analyze a representative bridging set (15–20 paired baseline and elevated research specimens) across both platforms to establish a validated linear conversion equation, ensuring seamless multi-year dataset continuity.
Bioanalytical parameters validated according to FDA Bioanalytical Method Validation (BMV) and ICH M10 guidelines.
Spectrophotometric and flow-cytometric optimization of capture antibody surface density and carbodiimide covalent coupling kinetics.
Optimization of biotin-to-protein labeling ratios and enzyme conjugate concentrations to maximize signal-to-background (AEB) ratios.
Formal dossier validation covering accuracy, intra/inter-assay precision, dilution linearity, parallelism, and freeze-thaw robustness.
Capture antibodies covalently coupled to carboxylated paramagnetic beads with optimized loading density.
Detector antibodies biotinylated at optimal D/P ratios and purified via spin-column desalt.
Custom conjugated beads capture target analytes from micro-samples in matrix-matched diluent.
Complexes sealed in 216,000 femtoliter microwells on Simoa optical discs and imaged for digital enzyme counting (AEB).
Absolute pg/mL concentrations calculated with comprehensive validation report and QC documentation.
A standardized pre-analytical framework ensuring high reagent stability and minimal matrix interference.
| Optimization Parameter | Why It Matters for Single-Molecule Assay Development | Intake Specification & Recommendation |
|---|---|---|
| Capture Antibody Quality | Antibody purity and buffer composition dictate EDC/NHS crosslinking efficiency; amine-containing buffers (Tris, glycine) inhibit coupling. | Antibodies should be carrier-free (BSA-free, azide-free) in PBS at ≥1.0 mg/mL concentration. |
| Biotinylation Ratio | Over-biotinylation blocks the antigen-binding CDR region; under-biotinylation reduces SBG enzyme recruitment and signal intensity. | We perform systematic D/P titration (typically 20:1 to 60:1 challenge ratio) to determine optimal binding avidity. |
| Minimum Required Dilution (MRD) | Biological matrices contain proteins and lipids that can cause non-specific binding and matrix suppression. | Establish standard 1:4 MRD in matrix-matched diluent supplemented with heterophilic blocking agents. |
| Freeze-Thaw & Reagent Stability | Coupled paramagnetic beads and biotinylated antibodies require stable long-term storage conditions for multi-batch studies. | Conjugated beads stored at 4 °C in blocking buffer (stable >6 months); calibrators aliquoted at −80 °C. |
| Sample Net Volume | Single-molecule digital counting requires minimal specimen input for high-throughput screening. | 15 μL net volume per well (30 μL recommended to support duplicate verification and analytical reserve). |
| Run Allocation & Balancing | Placing baseline and post-treatment cohorts on separate plates risks confounding treatment effects with batch variance. | We pre-plan plate layouts so that paired longitudinal timepoints and cohort groups are balanced across the same run. |
Empowering preclinical pipeline development, novel biomarker validation, and therapeutic lead optimization.
Develop bespoke single-molecule assays for novel therapeutic targets, neoantigens, and rare proteoforms lacking commercial kits.
Convert existing standard ELISA antibody pairs into digital bead-based assays to achieve 100- to 1,000-fold sensitivity gains.
Quantify ultra-trace circulating free payload toxins, linkers, and intact ADC molecules in micro-volume preclinical samples.
Engineer custom digital assays specific to novel phosphorylation, citrullination, or proteolytic cleavage neo-epitopes.
Build custom assays for non-traditional animal models (canine, porcine, ferret, non-human primate, zebrafish).
Deliver comprehensive bioanalytical validation dossiers, production-ready SOPs, and stabilized conjugated bead lots.
quality-controlled bioanalytical documentation and PhD-level consultation for every custom assay project.
Landmark peer-reviewed studies establishing single-molecule custom assay development and bioanalytical validation.
Study Design Takeaway: Seminal paper demonstrating how partitioning paramagnetic beads into femtoliter microwells enhances assay sensitivity by 1000-fold over ELISA.
Study Design Takeaway: Details technical parameters for Homebrew bead conjugation, detector biotinylation, and automated digital imaging.
Study Design Takeaway: Establishes standardized guidelines for defining LLOQ, intra/inter-assay precision, parallelism, and matrix spike-recovery in bioanalytical assays.
Study Design Takeaway: Validates method bridging protocols when migrating biomarker assays from legacy ECL to digital Simoa.
Study Design Takeaway: Regulatory benchmark framework governing fit-for-purpose biomarker validation and quality assurance.
Addressing common bioanalytical and project planning inquiries.
To develop a custom sandwich Simoa assay, we typically require: (1) a matched antibody pair (at least 1 mg of capture antibody and 0.5 mg of detector antibody, carrier-free in PBS without BSA or azide), and (2) a purified recombinant protein or peptide calibrator (at least 50–100 μg) for standard curve generation. If you do not have proprietary antibodies, our team can screen and source commercial pairs on your behalf.
A standard Homebrew assay development project is structured into clear phases: Phase 1 (Feasibility & Screening) is completed in 2–3 weeks; Phase 2 & 3 (Optimization & Matrix Qualification) take 2–3 weeks; and Phase 4 (Fit-for-Purpose Validation & Reporting) takes 2 weeks. Total turnaround is typically 4–8 weeks depending on matrix complexity.
In general, converting a well-characterized sandwich ELISA antibody pair to the Simoa digital platform results in a 100- to 1,000-fold improvement in lower limit of quantification (LLOQ). Targets that previously measured at 10–50 pg/mL on ELISA routinely achieve functional LLOQs of 0.01 to 0.10 pg/mL on Simoa.
Yes. Custom Homebrew assays can be multiplexed up to 4 targets per sample on the Simoa HD-X platform by using beads encoded with distinct fluorescent dye signatures. Each bead population is conjugated to a unique capture antibody, enabling simultaneous multi-analyte quantification from a single 15 μL sample.
All custom assay protocols, conjugation SOPs, validation dossiers, and assay data generated for client-specific proprietary targets belong 100% to the client. Creative Proteomics operates strictly as a fee-for-service CRO and claims zero IP ownership over client targets or custom assay methods.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×